Pharmacy chains activity analysis

Pharmacy chains activity analysis

Russian pharmaceuticals retail chain segment evaluation, both on the level of the state and in particular regions. Pharmacy chains development forecast


Product sales and separate market development forecast, based on unique mathematical models

Business and marketing plan development

Development of detailed business-plans, required to evaluate the reasonability of project start

Search of partners for contract production in Russia

Potential partners search and evaluation, based on their technical opportunities, appropriate experience, and reputation

Monitoring of import substitution

assessment of the main trends of import substitution policies and localization processes in the pharmaceutical market in Russia, the key beneficiaries and companies at risk

Pharmaceutical Drug Production in Russia (February 2024)

Thursday, March 28, 2024

In January–February 2024, Russian manufacturers produced 124.5 billion rubles’ worth of ready-made pharmaceutical drugs (manufacturer’s prices, VAT included), up 22.8% from the same period in 2023. In physical terms, it was 649 million packages, up 6.4% from January–February 2023. If calculated in minimum dosage units (MDU), the manufacture was 13.2 billion, up 10.8% from the same periods in 2023.

In February 2024, 69.2 billion rubles’ worth of ready-made pharmaceuticals were manufactured, up 33% from February 2023, which is the best monthly growth rate since March 2022, when it was 48% (last year, the highest monthly growth rate was 31.6%, in November). In physical terms, the manufacture was 351.5 million packages (up 4.6%) and 7.3 billion MDUs (up 8.4%).

The number of ready-made drug manufacturers continued to grow. In January–February 2024, it was 354, up 27 from January–February 2023. 46 out of those are foreign companies that have localized production in Russia. Among those, the companies that have their own production facilities account for the largest manufacture volumes, in particular Gedeon Richter, Servier, and KRKA. At the same time, the number of foreign companies went down by 6 from January–February 2023, but all of them produce very small volumes of drugs in bulk. In January–February 2024, the production volume by those companies went up 3% in packages from the same period in 2023.

The number of companies manufacturing prescription drugs was 288, up 18 from January–February 2023, while the number of brands was 1,178, up 95. Anti-tuberculosis Capreomycin had the best growth rates—its production increased 190 times against January–February 2023. That is the result of the low base effect, since the drug was hardly manufactured in 2022–2023, while about 25-30% of the average annual volume of the last two years was produced in January–February 2024. The drug was manufactured by three companies at once, with Promomed and Kraspharma contributing to the growth rates the most. Among the drugs with the largest production volumes in physical terms, the manufacture of Tadalafil grew 10 times against January–February 2023. The drug was almost entirely manufactured by Severnaya Zvezda.

As for OTC drugs, the number of manufacturers was 165, up 18 from January–February 2023, and the number of brands was 695, up 44. Ketoconazole Shampoo by Vertex had the highest growth rates—its production went up 67 times against January–February 2023. The drug has been produced since 2019 in very large volumes. Among the drugs with the largest production volumes, the manufacture of Xylen grew nearly 28 times against January–February 2023. The drug is produced at Abbott in Vladimir Oblast.

Pharmaceutical drug production in Russia, including production of pharmaceuticals of foreign companies on owned or contract plants, in physical (packages) and monetary terms (RUB, VAT included) (January 2023–February 2024)